midostaurin in c-kit or flt3-itd mutated t(8;21) aml
Published 4 years ago • 741 plays • Length 3:42Download video MP4
Download video MP3
Similar videos
-
2:08
comparing midostaurin to next-generation flt3 inhibitors in the frontline treatment of flt3-itd aml
-
3:56
radius results: midostaurin reduces relapse after asct in flt3-itd aml
-
0:59
midostaurin: a step forward in the treatment of flt3-mutated aml
-
3:12
go plus midostaurin and intensive chemotherapy in cbf and flt-mut aml
-
2:12
midostaurin for newly diagnosed flt3 aml: radius-x efficacy and safety data
-
1:13
cytometry versus morphology in the monitoring of aml
-
1:40
second-generation flt3 inhibitors in the treatment of flt3-itd aml
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
9:44
an update on the quantum-first trial: quizartinib plus chemotherapy in flt3-mutated aml
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
2:57
imetelstat for lr-mds: insights from the imerge trial
-
2:40
what we still don't know about the ratify study of midostaurin in aml
-
1:36
midostaurin and quizartinib: improving survival and day-to-day life in aml
-
0:56
the “controversial situations” seen in flt3-mutated aml patients
-
1:43
the drugs being used to treat newly diagnosed aml patients
-
1:39
quantum-first: flt3-itd-specific mrd clearance is associated with improved os in newly diagnosed aml
-
2:44
bmt ctn 1506/morpho: flt3-itd variant allele frequency and mrd data
-
3:21
tki maintenance after sct in flt3-itd positive aml
-
1:40
sf3b1 as therapeutic target in flt3/itd positive aml
-
2:28
midostaurin: the first drug to receive approval for aml since 2000
-
2:11
update on phase i/ii study of azacitidine, venetoclax and gilteritinib in patients with flt3 aml
-
1:32
the importance of cytogenetics and molecular profiling for accurate aml/mds diagnosis